Walleye Capital’s Lyell Immunopharma LYEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$445K Buy
+22,207
New +$519K ﹤0.01% 2757
2025
Q3
Sell
-29,230
Closed -$258K 4848
2025
Q2
$258K Buy
+29,230
New +$266K ﹤0.01% 3175
2023
Q1
Sell
-2,939
Closed -$204K 4188
2022
Q4
$204K Sell
2,939
-8,112
-73% -$806K ﹤0.01% 2037
2022
Q3
$1.62M Buy
+11,051
New +$1.5M 0.03% 671
2022
Q2
Sell
-8,047
Closed -$813K 2563
2022
Q1
$813K Buy
8,047
+7,447
+1,241% +$902K 0.02% 737
2021
Q4
$93K Buy
+600
New +$134K ﹤0.01% 1702

Other funds holding LYEL

Walleye Capital's LYEL Position: Q1 2026 in Review

Walleye Capital opened a new position in Lyell Immunopharma (LYEL) in Q1 2026: 22,207 shares worth $445K. The stake represents ﹤0.01% of the portfolio and ranks #2757 among its holdings. This is a return to the name: Walleye Capital previously reported a position in LYEL as recently as Q2 2025.

Walleye Capital first reported a position in LYEL in Q4 2021 and has held it in 6 quarters since. The position peaked at $1.62M in Q3 2022. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Walleye Capital held 22,207 shares of Lyell Immunopharma worth $445K as of Q1 2026.
  • Lyell Immunopharma was a new Walleye Capital position in Q1 2026.
  • Lyell Immunopharma made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2757 holding.
  • Walleye Capital first reported a position in Lyell Immunopharma in Q4 2021 and has held it in 6 quarters since.
  • Walleye Capital's Lyell Immunopharma position peaked at $1.62M in Q3 2022.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.